<DOC>
	<DOCNO>NCT00752687</DOCNO>
	<brief_summary>To evaluate safety , tolerability pharmacokinetics ABT-072 healthy volunteer anti-viral activity HCV infect subject .</brief_summary>
	<brief_title>A Study ABT-072 Healthy Hepatitis C Virus Genotype 1-Infected Adults</brief_title>
	<detailed_description>A blind , randomize , placebo-controlled trial study safety , tolerability , antiviral activity pharmacokinetic profile ABT-072 healthy HCV genotype-1 infect adult .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>Criteria Healthy Adults : Informed consent obtain Subject general good health If female , postmenopausal If female , pregnant If male , must surgically sterile partner must use birth control Body Mass Index 18 29 , inclusive Criteria HCVinfected Adults : Infected HCV least 6 month show either detectable HCV RNA reactive antibody , liver biopsy pathology indicative HCV infection , disclosure risk factor Subject infect HCV genotype 1 detectable HCV RNA &gt; 50,000 IU/mL Criteria Healthy Adults : If female , pregnant breast feed Positive HAVIgM , HBsAg , HCV Ab HIV Ab Within 6 month start study , drug alcohol abuse use nicotine product Alcohol intake within 48 hour prior study drug administration Criteria HCVinfected Adults : Need prescription overthecounter medication Child Pugh score &gt; 5 clinical evidence cirrhosis No cause liver disease HCV infection ALT AST &gt; 4 x ULN Creatinine &gt; ULN Clinically significant abnormal ECG HCV RNA level level assay quantification TSH value outside normal range</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Phase 1</keyword>
</DOC>